Andrew Armstrong

New Capabilities

Public discussant of the TALAPRO-3 data

The Food and Drug Administration approved talazoparib (Talzenna) plus enzalutamide (Xtandi) on October 26 for men whose metastatic prostate cancer carries mutations in DNA-repair genes and who have not yet started hormone therapy for castration-resistant disease. The clearance moves the pair into the earlier castration-sensitive stage, where the trial showed it cut the risk of the cancer spreading or the patient dying by 52%.

Updated Oct 29